An ongoing phase I clinical dose escalation and optimization trial explores the intraoperative use of an EpCAM-specific fluorescence agent in esophageal, gastric, and rectosigmoid cancer (Netherlands Trial Register, ID NL7363). The gene discussed is EPCAM; the disease is rectosigmoid carcinoma.